title: Comment on: Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.
authors.forename: R
authors.initials: R
authors.lastname: Cianci
authors.forename: F
authors.initials: F
authors.lastname: Casciano
authors.forename: G
authors.initials: G
authors.lastname: Costamagna
authors.forename: F
authors.initials: F
authors.lastname: Pandolfi
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D003106:Colon / Q000382:microbiology; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D016131:Lymphocyte Subsets / Q000276:immunology; D054892:Metagenome / Q000187:drug effects*; D008962:Models, Theoretical; D012294:Rifamycins / Q000008:administration & dosage*; D000078262:Rifaximin
chemical_list: D000900:Anti-Bacterial Agents; D016207:Cytokines; D007155:Immunologic Factors; D012294:Rifamycins; D000078262:Rifaximin